Interview With Rabbi Zac Kamenetz

Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.

Interview With Douglas K. Gordon

CEO of Silo Wellness, Douglas K. Gordon, speaks about the company’s expansion to the Frankfurt Exchange and the recent collaboration with the Bob Marley Estate.
Psilocybin’s Relationship with Creativity a ‘Complicated’ Affair

Psilocybin’s Relationship with Creativity a ‘Complicated’ Affair, Study Finds

New research points to a connection between psilocybin mushrooms and creativity.
Former Texas Gov. Rick Perry Champions Psychedelic Therapy for PTSD

Former Texas Gov. Rick Perry Champions Psychedelic Therapy for PTSD

Former Texas Governor, the Republican Rick Perry, is supporting legislation for psychedelic therapy to help veterans with PTSD.
Psilocybin As Effective as Lexapro in Treating Depression: Study

Psilocybin As Effective as Lexapro in Treating Depression: Study

The first study of its kind compares psilocybin and the antidepressant Lexapro in treating depression. The results are promising.
Bicycle Day Celebrates First Human LSD Trip

What Is Bicycle Day? Celebrating the First Human LSD Trip

April 19th is Bicycle Day — the first documented case of a human experience on LSD taken by chemist Albert Hoffman.

Digital Therapeutics and Psychedelic Medicines || MindMed ‘s SECRET WEAPON?!?

Digital Therapeutics and Psychedelic Medicines || MindMed's SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai's secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface. Instead of doing our usual "This Week In Psychedelic Stocks episode", I decided to discuss the article entitled "Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP" as it pertains to MindMed and Atai and because there wasn't a lot of interesting news for our usual Psychedelic segment. Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there's two reasons. 1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare. 2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology. I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! If you wish to collaborate, send us an email at: thepsychedelicinvestor@gmail.com Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com Time Stamps: 0:00 - Intro 10:08 - Implications for MindMed and Atai DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​ ​#MindmedStock​​ #MMEDNews

Interview With Stephen Murphy

Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
Psychedelic Business News Spotlight: April 16, 2021

Psychedelic Business News Spotlight: April 16, 2021

This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.

Psilocybin Trial Treating Depression CRUSHES It [Are We At A Turning Point?]

Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment. The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS! The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world. Though the study's primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives. And again, every secondary research objective heavily FAVORED psilocybin. This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ) Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel ​... ​ General thoughts. We've been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it'll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#psilocybin​​​​ #shroomboom